CO2018005920A2 - Composiciones y métodos para fabricar micropartículas de proteína - Google Patents

Composiciones y métodos para fabricar micropartículas de proteína

Info

Publication number
CO2018005920A2
CO2018005920A2 CONC2018/0005920A CO2018005920A CO2018005920A2 CO 2018005920 A2 CO2018005920 A2 CO 2018005920A2 CO 2018005920 A CO2018005920 A CO 2018005920A CO 2018005920 A2 CO2018005920 A2 CO 2018005920A2
Authority
CO
Colombia
Prior art keywords
methods
compositions
therapeutic protein
manufacturing
protein microparticles
Prior art date
Application number
CONC2018/0005920A
Other languages
English (en)
Spanish (es)
Inventor
Philip Brudnicki
Hunter Chen
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57708873&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO2018005920(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of CO2018005920A2 publication Critical patent/CO2018005920A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1658—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CONC2018/0005920A 2015-12-16 2018-06-08 Composiciones y métodos para fabricar micropartículas de proteína CO2018005920A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562268259P 2015-12-16 2015-12-16
PCT/US2016/067280 WO2017106716A1 (en) 2015-12-16 2016-12-16 Compositions and methods of manufacturing protein microparticles

Publications (1)

Publication Number Publication Date
CO2018005920A2 true CO2018005920A2 (es) 2018-06-20

Family

ID=57708873

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2018/0005920A CO2018005920A2 (es) 2015-12-16 2018-06-08 Composiciones y métodos para fabricar micropartículas de proteína

Country Status (22)

Country Link
US (1) US20200022917A1 (enExample)
EP (2) EP3389636B1 (enExample)
JP (2) JP7185526B2 (enExample)
KR (1) KR102714544B1 (enExample)
CN (2) CN114404371A (enExample)
AU (2) AU2016369557B2 (enExample)
BR (1) BR112018010743B1 (enExample)
CA (1) CA3003654A1 (enExample)
CL (2) CL2018001623A1 (enExample)
CO (1) CO2018005920A2 (enExample)
DK (1) DK3389636T3 (enExample)
EA (2) EA201891164A1 (enExample)
ES (2) ES2981791T3 (enExample)
HU (1) HUE060148T2 (enExample)
IL (3) IL286601B2 (enExample)
MX (2) MX2018005384A (enExample)
MY (1) MY200764A (enExample)
PH (2) PH12018500830A1 (enExample)
PL (1) PL3389636T3 (enExample)
SG (2) SG11201803197UA (enExample)
WO (1) WO2017106716A1 (enExample)
ZA (2) ZA201802706B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11291636B2 (en) 2011-11-18 2022-04-05 Regeneron Pharmaceuticals, Inc. Polymer protein microparticles

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017364077A1 (en) 2016-11-22 2019-06-20 Elektrofi, Inc. Particles comprising a therapeutic or diagnostic agent and suspensions and methods of use thereof
WO2019023392A1 (en) 2017-07-25 2019-01-31 Elektrofi, Inc. FORMATION OF PARTICLES COMPRISING AGENTS
EP4650360A2 (en) * 2017-08-18 2025-11-19 Regeneron Pharmaceuticals, Inc. Image capillary isoelectric focusing to analyze protein variants in a sample matrix
GB201718888D0 (en) * 2017-11-15 2017-12-27 Ucb Biopharma Sprl Method
US12156900B2 (en) 2017-11-17 2024-12-03 Amgen Inc. VEGFR-Fc fusion protein formulations
US12115262B2 (en) 2018-05-24 2024-10-15 Elektrofi, Inc. Particles comprising a therapeutic or diagnostic agent and suspensions and methods of use thereof
EP3917500A2 (en) 2019-01-31 2021-12-08 Elektrofi, Inc. Particle formation and morphology
JP7781743B2 (ja) 2019-09-13 2025-12-08 エレクトロフィ，インコーポレイテッド 疾患の処置のための治療用生物学的作用剤の送達のための組成物及び方法
EP4057941A4 (en) * 2019-11-15 2024-05-29 Silk Technologies Ltd. STABLE SILK-DERIVED PROTEIN FORMULATIONS
US11730793B2 (en) * 2019-11-25 2023-08-22 Regeneron Pharmaceuticals, Inc. Sustained release formulations using non-aqueous emulsions
US20230094393A1 (en) * 2020-02-07 2023-03-30 Elektrofi, Inc. Peptide particles and methods of formation
AU2021257476A1 (en) 2020-04-17 2022-11-03 Elektrofi, Inc. Methods of forming particles by continuous droplet formation and dehydration
US12239687B2 (en) * 2020-11-25 2025-03-04 Regeneron Pharmaceuticals, Inc. Sustained release formulations using non-aqueous membrane emulsification

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4210529A (en) 1974-12-26 1980-07-01 Midwest Research Institute Blood compatible polymers and applications thereof
US4304767A (en) 1980-05-15 1981-12-08 Sri International Polymers of di- (and higher functionality) ketene acetals and polyols
US4764364A (en) 1986-02-25 1988-08-16 S R I International Method of preparing bioerodible polymers having pH sensitivity in the acid range and resulting product
US5468468A (en) 1989-02-09 1995-11-21 The United States Of America, As Represented By The Secretary Of The Department Of Health & Human Services Method for making a monoclonal antibody, monoclonal antibodies to α PD
US5104221A (en) 1989-03-03 1992-04-14 Coulter Electronics Of New England, Inc. Particle size analysis utilizing polarization intensity differential scattering
DK0939121T4 (da) 1989-09-12 2008-02-04 Ahp Mfg B V TNF-bindende proteiner
US5814464A (en) 1994-10-07 1998-09-29 Regeneron Pharma Nucleic acids encoding TIE-2 ligand-2
US6019968A (en) * 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
US5968543A (en) 1996-01-05 1999-10-19 Advanced Polymer Systems, Inc. Polymers with controlled physical state and bioerodibility
EP0913177A1 (de) * 1997-11-03 1999-05-06 Roche Diagnostics GmbH Verfahren zur Herstellung trockener, amorpher Produkte enthaltend biologisch aktive Materialien mittels Konvektionstrocknung, insbesondere Sprühtrocknung
US6284282B1 (en) * 1998-04-29 2001-09-04 Genentech, Inc. Method of spray freeze drying proteins for pharmaceutical administration
US6927044B2 (en) 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
US7303746B2 (en) 1999-06-08 2007-12-04 Regeneron Pharmaceuticals, Inc. Methods of treating eye disorders with modified chimeric polypeptides
US7306799B2 (en) 1999-06-08 2007-12-11 Regeneron Pharmaceuticals, Inc. Use of VEGF inhibitors for treatment of eye disorders
US7070959B1 (en) 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
US7205275B2 (en) 2001-10-11 2007-04-17 Amgen Inc. Methods of treatment using specific binding agents of human angiopoietin-2
US7521053B2 (en) 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
US7658924B2 (en) 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
KR100562195B1 (ko) 2002-03-08 2006-03-20 에이에스엠엘 네델란즈 비.브이. 리소그래피용 마스크, 마스크 제조방법, 리소그래피장치및 디바이스제조방법
DE10339197A1 (de) * 2003-08-22 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Sprühgetrocknete amorphe Pulver mit geringer Restfeuchte und guter Lagerstabilität
JP4627425B2 (ja) 2004-09-29 2011-02-09 本田技研工業株式会社 無段変速機の変速制御装置
CN105085678B (zh) 2004-12-21 2019-05-07 阿斯利康公司 血管生成素-2的抗体及其应用
PL2100618T3 (pl) 2005-06-17 2014-07-31 Imclone Llc Przeciwciało anty-PDGFR alfa do zastosowania w leczeniu przerzutowego raka kości
WO2007033216A2 (en) 2005-09-12 2007-03-22 Beth Israel Deaconess Medical Center Methods and compositions for the treatment and diagnosis of diseases characterized by vascular leak, hypotension, or a procoagulant state
CN104434770A (zh) * 2006-06-16 2015-03-25 瑞泽恩制药公司 适合玻璃体内施用的vegf拮抗剂的制剂
BRPI0810374A2 (pt) 2007-04-17 2014-10-29 Imclone Llc Inibidores específicos do pdgfrbeta
AU2009204863B2 (en) * 2008-01-15 2015-07-16 AbbVie Deutschland GmbH & Co. KG Powdered protein compositions and methods of making same
PL2274008T3 (pl) 2008-03-27 2014-07-31 Zymogenetics Inc Kompozycje i sposoby hamowania PDGFRbeta i VEGF-A
JP2012520311A (ja) * 2009-03-11 2012-09-06 プレキシコン インコーポレーテッド Ｒａｆキナーゼの阻害のためのピロロ［２，３−ｂ］ピリジン誘導体
JO3182B1 (ar) 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
US8754195B2 (en) 2010-07-02 2014-06-17 Medimmune, Llc Antibody formulations
JOP20190250A1 (ar) * 2010-07-14 2017-06-16 Regeneron Pharma صيغ مستقرة تحتوي على الأجسام المضادة لمضاد عامل نمو الأعصاب
AR087305A1 (es) * 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
ES2909777T3 (es) * 2011-11-18 2022-05-10 Regeneron Pharma Formulación de liberación prolongada que comprende micropartículas para su uso en el humor vítreo del ojo para tratar trastornos oculares vasculares
NZ701915A (en) 2012-05-18 2016-11-25 Genentech Inc High-concentration monoclonal antibody formulations
AR091967A1 (es) * 2012-08-02 2015-03-11 Sanofi Sa Articulo de fabricacion que comprende aflibercept o 2iv-aflibercept
JO3405B1 (ar) 2013-01-09 2019-10-20 Regeneron Pharma الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11291636B2 (en) 2011-11-18 2022-04-05 Regeneron Pharmaceuticals, Inc. Polymer protein microparticles
US11951216B2 (en) 2011-11-18 2024-04-09 Regeneron Pharmaceuticals, Inc. Polymer protein microparticles

Also Published As

Publication number Publication date
IL286601B2 (en) 2023-09-01
IL302211A (en) 2023-06-01
CN108366968A (zh) 2018-08-03
PH12021550603A1 (en) 2021-11-03
EA201891164A1 (ru) 2018-11-30
BR112018010743A2 (en) 2018-11-21
CN114404371A (zh) 2022-04-29
SG11201803197UA (en) 2018-05-30
AU2016369557A1 (en) 2018-06-07
JP2019504825A (ja) 2019-02-21
SG10202007834VA (en) 2020-09-29
EP4059492A1 (en) 2022-09-21
EP4059492B1 (en) 2024-04-17
MX2024000362A (es) 2024-01-26
MY200764A (en) 2024-01-14
JP7185526B2 (ja) 2022-12-07
HUE060148T2 (hu) 2023-02-28
EP3389636A1 (en) 2018-10-24
ZA202304376B (en) 2024-08-28
AU2016369557B2 (en) 2022-10-20
CL2018001623A1 (es) 2018-07-20
BR112018010743B1 (pt) 2024-02-15
IL286601B1 (en) 2023-05-01
EP3389636B1 (en) 2022-07-20
CN108366968B (zh) 2022-02-18
PL3389636T3 (pl) 2022-11-28
KR20180088836A (ko) 2018-08-07
ES2981791T3 (es) 2024-10-10
PH12018500830A1 (en) 2018-10-29
IL259204A (en) 2018-07-31
JP7554243B2 (ja) 2024-09-19
ZA201802706B (en) 2023-12-20
IL259204B (en) 2021-10-31
AU2022291549B2 (en) 2024-08-08
AU2022291549A1 (en) 2023-02-02
EA202192290A1 (ru) 2022-02-28
WO2017106716A1 (en) 2017-06-22
DK3389636T3 (da) 2022-09-19
BR112018010743A8 (pt) 2019-02-26
ES2927348T3 (es) 2022-11-04
US20200022917A1 (en) 2020-01-23
IL286601A (en) 2021-10-31
CL2023002345A1 (es) 2024-03-15
MX2018005384A (es) 2018-08-16
KR102714544B1 (ko) 2024-10-10
CA3003654A1 (en) 2017-06-22
HK1251461A1 (zh) 2019-02-01
JP2022185057A (ja) 2022-12-13

Similar Documents

Publication Publication Date Title
CO2018005920A2 (es) Composiciones y métodos para fabricar micropartículas de proteína
EA201691582A1 (ru) Новые фармацевтические препараты
EP3600563C0 (en) PHARMACEUTICAL COMPOSITIONS COMPRISING VITAMIN D3 AND HYALURONIC ACID
SG10201808104RA (en) Cenicriviroc for the treatment of fibrosis
MX2021000550A (es) Forma de dosis orales de liberacion sostenida de tofacitinib.
MX2016014320A (es) Composiciones de suspension de liberacion prolongada.
MX2021011906A (es) Composiciones de liberacion retardada de linaclotida.
MX383706B (es) Composiciones de cenicriviroc y métodos para elaborarlas y usarlas.
CL2016000063A1 (es) Nuevos derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen.
MX2015015409A (es) Proceso para la preparacion de eritrocitos cargados con una o mas sustancias de interes farmaceutico y eritrocitos asi obtenidos.
MX390461B (es) Metodos y composiciones particularmente para el tratamiento del trastorno por deficit de atencion
BR112015025814A2 (pt) composição farmacêutica para uso inalatório, processo para a preparação de uma composição farmacêutica, composição sólida para uso como um diluente de pós para inalação e kit para a administração de um fármaco como pó para inalação
MX2018012618A (es) Composiciones farmaceuticas orales de mesalazina.
MX2020004107A (es) Tabletas de deferiprona de liberacion retrasada y metodos de uso de las mismas.
PH12016502243A1 (en) Pharmaceutical compositions for treating infectious diseases
MX2016006087A (es) Formulaciones de desintegracion rapida y metodos de uso.
MX2016015261A (es) Dispersion solida de allisartan isoproxilo y su composicion.
MX2017008983A (es) Composición farmaceútica de sulfonamida.
MX2023003000A (es) Formulaciones de liberacion modificada de viloxacina.
WO2014165513A3 (en) Ethylsulfonated hyaluronic acid biopolymers and methods of use thereof
TN2016000484A1 (en) Ceritinib formulation.
MX2016005227A (es) Polipéptidos de acción prolongada y métodos para su producción y administración.
MX2016002502A (es) Composiciones farmaceuticas de bendamustina.
CL2017001680A1 (es) Composición farmacéutica para el tratamiento de enfermedades gastrointestinales
AR094391A1 (es) Formulaciones de lorazepam de liberación sostenida